- Trials with a EudraCT protocol (65)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
65 result(s) found for: Gene dosage.
Displaying page 1 of 4.
EudraCT Number: 2013-004427-37 | Sponsor Protocol Number: ESPP001 | Start Date*: 2014-10-01 | |||||||||||
Sponsor Name:PARENT PROJECT ONLUS | |||||||||||||
Full Title: Multicentre, randomised, double-blind, dose titration design in patients with Duchenne muscular dystrophy to evaluate the efficacy and the tolerability of the combinations of Ibuprofen (200 mg bid)... | |||||||||||||
Medical condition: Restrictive respiratory syndrome with frequent pulmonary infections and cardiomyopathy. wasting of skeletal muscle, severe local inflammation and, at least initially, muscle regeneration. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002520-33 | Sponsor Protocol Number: SNT-II-1 | Start Date*: 2005-09-06 |
Sponsor Name:Santhera Pharmaceuticals LLC | ||
Full Title: A Phase IIa double blind, randomised, placebo controlled, single centre study at the university of Leuven to assess the efficacy and tolerability of idebenone in 10 - 16 year old males with cardiac... | ||
Medical condition: Duchenne Muscular Dystrophy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000902-30 | Sponsor Protocol Number: SB-999920/040 | Start Date*: 2005-12-09 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene Expression in Rheumatoid Arthritis Patients | ||
Medical condition: Rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000831-21 | Sponsor Protocol Number: HZNP-DAX-202 | Start Date*: 2023-02-06 | |||||||||||
Sponsor Name:Horizon Therapeutics Ireland DAC | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF DAXDILIMAB SUBCUTANEOUS INJECTION IN REDUCING DISEASE ACTIVITY I... | |||||||||||||
Medical condition: Discoid Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004958-29 | Sponsor Protocol Number: CHUBX2019/25 | Start Date*: 2020-04-07 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: EFFECT OF POLYETHYLENE GLYCOL TREATMENT ON INTESTINAL INFLAMMATION ASSOCIATED WITH CYSTIC FIBROSIS IN CHILDREN | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004252-37 | Sponsor Protocol Number: IPH1101-204 | Start Date*: 2007-10-11 | |||||||||||
Sponsor Name:Innate Pharma | |||||||||||||
Full Title: A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease | |||||||||||||
Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001314-41 | Sponsor Protocol Number: 69501 | Start Date*: 2019-05-06 |
Sponsor Name: | ||
Full Title: Kinetics of ivacaftor at Switch Orkambi Symkevi study | ||
Medical condition: Cystic fibrosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017253-35 | Sponsor Protocol Number: PS1/001/09 | Start Date*: 2010-08-20 |
Sponsor Name:Oxford BioMedica (UK) Ltd | ||
Full Title: A multicentre, open-label extension study to determine the long term safety, tolerability and efficacy of ProSavin® in patients with bilateral, idiopathic Parkinson’s disease | ||
Medical condition: Patients with bilateral, idiopathic Parkinson's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006076-38 | Sponsor Protocol Number: RLBUHT3173 | Start Date*: 2007-04-26 |
Sponsor Name:University of Liverpool [...] | ||
Full Title: The Liverpool HIV TDM Registry: Studying influences upon plasma HIV drug exposure | ||
Medical condition: Pharmacogenetic study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification wil... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003425-81 | Sponsor Protocol Number: RLBUHT2763 | Start Date*: 2007-03-29 |
Sponsor Name:University of Liverpool | ||
Full Title: Host genetic factors influencing drug disposition and response to HIV treatment | ||
Medical condition: Pharmacogeneric study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification will... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004534-23 | Sponsor Protocol Number: GATRA2016 | Start Date*: 2017-04-11 | |||||||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||||||||||||
Full Title: Pilot study of Antithrombin supplementation during Extracorporeal Membrane Oxigenation | |||||||||||||||||||||||
Medical condition: Adult patients requiring veno-venous Extracorporeal circulation (ECMO) as a support for respiratory failure | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000237-17 | Sponsor Protocol Number: NL-80249 | Start Date*: 2022-12-15 |
Sponsor Name: | ||
Full Title: Prospective clinical trial to evaluate the efficacy of acetazolamide for the treatment of cystoid macular edema in inherited retinal dystrophies: the CAR trial | ||
Medical condition: Cystoid Macular Edema in inherited retinal dystrophies | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002392-28 | Sponsor Protocol Number: RM-493-Supplementation-Therapy | Start Date*: 2014-11-28 |
Sponsor Name:Charité Univeritaetsmedizin Berlin | ||
Full Title: Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity | ||
Medical condition: Body weight is regulated within the hypothalamus. In rare cases mutations in genes, which are embedded in the signaling cascades of the hypothalamus lead to early onset severe obesity. POMC is one ... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020069-26 | Sponsor Protocol Number: DMD114044 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy. | |||||||||||||
Medical condition: Duchenne muscular dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) IT (Completed) PL (Completed) CZ (Completed) ES (Completed) NO (Completed) DK (Completed) HU (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005401-28 | Sponsor Protocol Number: AOI2021ME_PICKERING | Start Date*: 2022-01-26 |
Sponsor Name:University Hospital of Clermont-Ferrand | ||
Full Title: Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling: Randomized pilot clinical trial | ||
Medical condition: postmenopausal osteoporosis | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004527-20 | Sponsor Protocol Number: PTC124-GD-020-DMD | Start Date*: 2013-07-30 | ||||||||||||||||
Sponsor Name:PTC Therapeutics, Inc | ||||||||||||||||||
Full Title: A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy | ||||||||||||||||||
Medical condition: Nonsense mutation dystrophinopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: BE (Completed) CZ (Completed) SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) PL (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006773-92 | Sponsor Protocol Number: FARM6TT8SP | Start Date*: 2008-07-23 | ||||||||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI PERUGIA | ||||||||||||||||||
Full Title: Sodium Valproate in the treatment of medication overuse headache: a controlled randomized clinical trial. | ||||||||||||||||||
Medical condition: medication overuse headache | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000359-26 | Sponsor Protocol Number: ESTEVE-SANF-201 | Start Date*: 2016-04-29 |
Sponsor Name:Laboratorios del Dr. Esteve, S.A. | ||
Full Title: Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients wit... | ||
Medical condition: Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome) is an inherited lysosomal storage disease caused by a specific lysosomal enzyme deficiency that leads to intracellular accumulation of the ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004459-38 | Sponsor Protocol Number: TREACE_2015 | Start Date*: 2016-02-24 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | ||||||||||||||||||
Full Title: EXPLORATIVE STUDY TO IDENTIFY A SPECIFIC TRANSCRIPTOMIC PROFILE FOR PREDICTING THE MAJOR ADVERSE EFFECTS ASSOCIATED WITH CERTICAN (EVEROLIMUS) IN RENAL TRANSPLANT RECIPIENTS: A PHARMACOGENOMIC APPR... | ||||||||||||||||||
Medical condition: kidney transplant | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018412-32 | Sponsor Protocol Number: DMD114117 | Start Date*: 2010-08-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambul... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) FR (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
